Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) stock enjoyed a major increase of 14.3% on 8/2/24. The shares closed at $50.47. Moreover, exceptionally high trading volume at 282% of normal accompanied the advance. The stock has performed in line with the market over the last nine months and has risen 12.0% during the last week.
Current PriceTarget Research Rating
RARE is expected to be a modest Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Ultragenyx Pharmaceutical has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Ultragenyx Pharmaceutical has a poor Power Rating of 29 and a very low Appreciation Score of 3, triggering the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment